On the contrary, the adjunction of elotuzumab to the Vd backbone (EloVd) failed to reach statistical significance in the improvement of PFS (HR 0.72, 95% CI 0.49–1.06) in a phase II study [ 49 ].
← all excerpts
Three Drug Combinations in the Treatment of Fit Elderly Multiple Myeloma Patients.
1
—
—